<DOC>
	<DOCNO>NCT00724867</DOCNO>
	<brief_summary>This continuation study provide continue treatment subject complete study HGS1006-C1056 United States , evaluate long-term safety efficacy belimumab ( LymphoStat-B™ ) subject SLE disease .</brief_summary>
	<brief_title>A Continuation Trial Subjects With Lupus Who Completed Protocol HGS1006-C1056 United States</brief_title>
	<detailed_description>This long-term continuation study provide continue treatment subject complete study HGS1006-C1056 United States . This study evaluate long-term safety efficacy belimumab ( LymphoStat-B™ ) subject SLE disease .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Have complete HGS1006C1056 protocol United States Week 72 visit . Be able receive 1st dose belimumab HGS 1006c1066 four week last dose HGS1006c1056 . Have develop medical disease condition make subject unsuitable study opinion physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Belimumab</keyword>
	<keyword>SLE</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Lupus</keyword>
	<keyword>Autoimmune Diseases</keyword>
</DOC>